Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia

Cancer Letters

Volumn 107, Issue 2, 1996, Pages 265-272

  Sharma, Amarnath ^a   Sharma, Uma S ^a   Straubinger, Robert M ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b NONE

Author keywords

Intraperitoneal therapy; Liposomes; P388 leukemia; Paclitaxel

Indexed keywords

CREMOPHOR; LIPOSOME; PACLITAXEL;

ABDOMINAL PAIN; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG CLEARANCE; DRUG FORMULATION; DRUG SOLUBILITY; DRUG TOLERABILITY; FEMALE; HYPOTHESIS; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA P 388; MOUSE; NONHUMAN; PERITONEAL CAVITY; PERITONEUM CANCER; PRIORITY JOURNAL;

ANIMALIA;

EID: 0030598163     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3835(96)04380-7     Document Type: Article

References (25)

1. [1] Wani, M.C., Taylor, H.L., Wall, M.E., Coggon, P. and McPhail, A.T. (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia, J. Am. Chem. Soc., 93, 2325-2327.
2. [2] McGuire, W.P., Rowinsky, E.K., Rosenshein, N.B., Grumbine, F.C., Ettinger, D.S., Armstrong, D.K. and Donehower, R.C. (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms, Ann. Intern. Med., 111, 273-279.
3. [3] Markman, M., Rowinsky, E., Hakes, T., Reichman, B., Jones, W., Lewis, J.L. Jr., Rubin, S., Curtin, J., Barakat, R., Phillips, M., Hurowitz, L., Almadrones, L. and Hoskins, W. (1992) Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study, J. Clin. Oncol., 10, 1485-1491.
4. [4] Rowinsky, E.K., Donehower, R.C., Jones, R.J. and Tucker, R.W. (1988) Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol, Cancer Res., 48, 4093-4100.
5. [5] Bicher, A., Levenbach, C., Burke, T.W., Morris, M., Warner, D., DeJesus, Y. .and and Gershenson, D.M. (1995) Infusion site soft-tissue injury after paclitaxel administration, Cancer, 76, 116-120.
6. [6] Riondel, J., Jacrot, M., Fessi, H., Puisieux, F. and Poiter, P. (1992) Effects of free and liposome-encapsulated taxol on two brain tumors xenografted into nude mice, In Vivo, 6, 23-28.
7. [7] Bartoli, M.H., Boitard, M., Fessi, H., Beriel, H., Devissaguet, J.H., Picot, F. and Puisieux, F. (1990) In vitro and in vivo antitumor activity of free and encapsulated taxol, J. Microencapsulation, 7, 191-197.
8. [8] Straubinger, R.M., Sharma, A., Murray, M. and Mayhew, E. (1993) Novel taxol formulations: taxol-containing liposomes, J. Natl. Cancer Inst. Monogr., 15, 69-78.
9. [9] Sharma, A., Mayhew, E. and Straubinger, R.M. (1993) Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model, Cancer Res., 53, 5877-5881.
10. [10] Sharma, A. and Straubinger, R.M. (1994) Novel taxol formulations: preparation and characterization of taxol-containing liposomes, Pharm. Res., 11, 889-896.
11. [11] Forssen, E. and Tökés, Z. (1983) Attenuation of dermal toxicity of adriamycin by liposome encapsulation, Cancer Treat. Rep., 67, 481-484.
12. [12] Mayhew, E., Rustum, Y. and Vale, W. (1984) Inhibition of liver metastases of M5076 tumor by liposome-entrapped adriamycin, Cancer Drug Delivery, 1, 43-58.
13. [13] Sharma, A., Conway, W. and Straubinger, R. (1994) Reversed-phase high performance liquid Chromatographic determination of taxol in mouse plasma, J. Chromatogr. B, 655, 315-319.
14. [14] Bartlett, G.R. (1959) Phosphorus assay in column chromatography, J. Biol. Chem., 234, 466-468.
15. [15] Rose, W.C. (1992) Taxol: a review of its preclinical in vivo antitumor activity, Anti-Cancer Drugs, 3, 311-321.
16. [16] Parsons, J., Bellnier, D., Johnson, P., Oseroff, A., Sharma, A., Bernacki, R. and Greco, W. (1995) Computer hardware/software system for recording and analyzing data from photodynamic therapy and chemotherapy rodent tumor growth, Proc. Am. Assoc. Cancer Res., 36, 609.
17. [17] Dedrick, R., Myers, C., Bungay, P. and DeVita, V Jr. (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer, Cancer Treat. Rep., 62, 1-11.
18. [18] Myers, C. (1984) The use of intraperitoneal chemotherapy in the treatment of ovarian cancer, Semin. Oncol., 11, 275-284.
19. [19] Lorenz, W., Riemann, H.J., Schmal, A., Schult, H., Lang, S., Ohmann, C., Weber, D., Kapp, B., Luben, L. and Doenicke, A. (1977) Histamine release in dogs by Cremophor EL and its derivatives: oxyethylated oleic acid is the most effective constituent, Agents Actions, 7, 63-67.
20. [20] Dye, D. and Watkins, J. (1980) Suspected anaphylactic reaction to Cremophor EL, Br. Med. J., 280, 1353.
21. [21] Weiss, R.B., Donehower, R.C., Wiernik, P.H., Ohnuma, T., Gralla, R.J., Trump, D.L., Baker, J.R., VanEcho, D.A., VonHoff, D.D. and Leyland-Jones, B. (1990) Hypersensitivity reactions from taxol, J. Clin. Oncol., 8, 1263-1268.
22. [22] Rowinsky, E.K., Onetto, N., Canetta, R.M. and Arbuck, S.G. (1992) Taxol: the first of the taxanes, an important new class of antitumor agents, Semin. Oncol., 19, 646-662.
23. [23] Rowinsky, E., Chaudhry, V., Forastiere, A., Sartorius, S., Ettinger, D., Grochow, L., Lubejko, B., Cornblath, D. and Donehower, R. (1993) A phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting, J. Clin. Oncol., 11, 2010-2020.
24. [24] Seidman, A., Reichman, B., Crown, J., Yao, T., Heelan, R., Hakes, T., Lebwohl, D., Gilewski, T., Surbone, A., Currie, V., Hudis, C., Klecker, R., Jamis-Dow, C., Collins, J., Quinlivan, S., Berkery, R., Toomasi, F., Canetta, R. and Norton, L. (1993) Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary report, J. Natl. Cancer Inst. Monographs, 15, 171-176.
25. [25] Markman, M. (1993) Optimal versus maximally tolerated dose in cancer chemotherapy treatment, J. Cancer Res. Oncol., 119, 576-577.